Literature DB >> 15531834

Management of meningococcemia.

Jasjit Singh1, Antonio C Arrieta.   

Abstract

Meningococcemia causes substantial morbidity and mortality worldwide, usually in the term of fulminant disease. This paper reviews the background, pathophysiology, clinical manifestations, and treatment of this entity, along with prevention measures and public health issues to be considered. The authors present updated information on breakthroughs in the understanding of genetic predisposition to invasive disease. The status of adjunctive treatment modalities such as monoclonal antibodies and activated protein C, and progress in conjugate vaccine development and implementation are also addressed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15531834

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  20 in total

1.  The management of fever and petechiae: making sense of rash decisions.

Authors:  P A Brogan; A Raffles
Journal:  Arch Dis Child       Date:  2000-12       Impact factor: 3.791

2.  Features and outcome in meningococcal disease presenting with maculopapular rash.

Authors:  O Marzouk; A P Thomson; J A Sills; C A Hart; F Harris
Journal:  Arch Dis Child       Date:  1991-04       Impact factor: 3.791

3.  Epidemiology and clinical management of meningococcal disease in west Gloucestershire: retrospective, population based study.

Authors:  P A Wylie; D Stevens; W Drake; J Stuart; K Cartwright
Journal:  BMJ       Date:  1997-09-27

Review 4.  Severe meningococcal disease in childhood.

Authors:  P B Baines; C A Hart
Journal:  Br J Anaesth       Date:  2003-01       Impact factor: 9.166

5.  Adrenocorticotropic hormone and cortisol levels in relation to inflammatory response and disease severity in children with meningococcal disease.

Authors:  J B van Woensel; M H Biezeveld; A M Alders; A J Eerenberg; E Endert; E C Hack; I A von Rosenstiel; T W Kuijpers
Journal:  J Infect Dis       Date:  2001-12-03       Impact factor: 5.226

6.  Invasive meningococcal disease in adolescents and young adults.

Authors:  L H Harrison; M A Pass; A B Mendelsohn; M Egri; N E Rosenstein; A Bustamante; J Razeq; J C Roche
Journal:  JAMA       Date:  2001-08-08       Impact factor: 56.272

7.  Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group.

Authors:  M Levin; P A Quint; B Goldstein; P Barton; J S Bradley; S D Shemie; T Yeh; S S Kim; D P Cafaro; P J Scannon; B P Giroir
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

8.  Genetic influence on cytokine production and fatal meningococcal disease.

Authors:  R G Westendorp; J A Langermans; T W Huizinga; A H Elouali; C L Verweij; D I Boomsma; J P Vandenbroucke; J P Vandenbrouke
Journal:  Lancet       Date:  1997-01-18       Impact factor: 79.321

9.  Serogroup Y meningococcal disease in Chicago, 1991-1997.

Authors:  J A Racoosin; C G Whitney; C S Conover; P S Diaz
Journal:  JAMA       Date:  1998 Dec 23-30       Impact factor: 56.272

10.  Indications for the immunological evaluation of patients with meningitis.

Authors:  Gary D Overturf
Journal:  Clin Infect Dis       Date:  2002-12-31       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.